AstraZeneca Pharma India has received a favorable order from the Commissioner of Income-tax (Appeals) concerning an assessment year dispute. The order pertains to an appeal against an erroneous addition made by the Centralized Processing Centre (CPC). The CIT(A) directed the Assessing Officer to remove the addition after verification. The estimated favorable tax impact is approximately Rs. 3.30 crore.
Resolution of Tax Dispute
AstraZeneca Pharma India announced the receipt of an order from the Commissioner of Income-tax (Appeals) (CIT(A)) on November 26, 2025, related to the assessment year 2020-21. This order addresses a dispute arising from an appeal filed by the company. The underlying issue involves an erroneous addition of Rs. 13.11 crore that was previously made by the Centralized Processing Centre (CPC).
Details of the CIT(A) Order
The CIT(A) order instructs the Assessing Officer to remove the previously added amount, contingent on verification of AstraZeneca Pharma India’s claim. This development is seen as positive for the company, effectively resolving the dispute at this stage.
Financial Impact
The estimated favorable tax impact resulting from the CIT(A) order is approximately Rs. 3.30 crore. AstraZeneca Pharma India will now coordinate with the Assessing Officer to ensure the order is implemented in accordance with the CIT(A)’s directives.
Source: BSE
